Spoken Alpha
LFCR
LIFECORE BIOMEDICAL, INC. \DE\
Overview
Lifecore Biomedical manufactures pharmaceutical-grade hyaluronic acid and provides contract development and manufacturing services for complex sterile injectable products in syringes, vials, and cartridges.
LIFECORE BIOMEDICAL, INC. \DE\ is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $207.8M market cap.
LFCR missed consensus EPS by 0.4% in Q2 FY2026, reported May 30, 2026.
17 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-03-1614 Q&A exchanges
- Q3 FY2025Earnings2025-04-039 Q&A exchanges
- Q2 FY2025Earnings2025-01-0214 Q&A exchanges
- Q1 FY2025Earnings2024-10-0416 Q&A exchanges
- Q4 FY2024Earnings2024-08-276 Q&A exchanges
- Q4 FY2023Earnings2023-08-311 Q&A exchange
- Q3 FY2023Earnings2023-06-01
- Q2 FY2023Earnings2023-03-17
- Q1 FY2023Earnings2022-10-0621 Q&A exchanges
- Q4 FY2022Earnings2022-08-1017 Q&A exchanges
- Q3 FY2022Earnings2022-04-0520 Q&A exchanges
- Q2 FY2022Earnings2022-01-0519 Q&A exchanges
- Q1 FY2022Earnings2021-09-2928 Q&A exchanges
- Q4 FY2021Earnings2021-07-2823 Q&A exchanges
- Q3 FY2021Earnings2021-04-0833 Q&A exchanges
- Q2 FY2021Earnings2021-01-0631 Q&A exchanges
- Q1 FY2021Earnings2020-10-0727 Q&A exchanges
History
Earnings history
- Q2 FY20262026-05-30EPS$-0.43 vs $-0.30-44.9%Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-05-30 | $-0.43 | $-0.30 | -44.9% | — | — | — | EODHD |
Source: EODHD. LFCR reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks LFCR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 9/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $0.44 | $0.49 | -10.2% | -0.4% | +1.4% |
| Q4 FY2025 | $0.57 | $0.63 | -9.6% | -3.2% | -3.1% |
| Q3 FY2025 | $0.42 | $0.46 | -8.7% | +2.8% | +2.3% |
| Q2 FY2025 | $0.67 | $0.69 | -2.7% | +7.0% | +7.8% |
| Q1 FY2024 | $0.45 | $0.46 | -1.2% | +2.7% | +1.1% |
| Q4 FY2024 | $0.47 | $0.49 | -4.8% | +6.7% | +5.5% |
| Q3 FY2024 | $0.61 | $0.61 | +0.7% | +5.1% | +7.9% |
| Q2 FY2024 | $0.61 | $0.65 | -6.1% | -2.9% | -0.5% |
| Q1 FY2023 | $0.76 | $0.83 | -9.0% | +2.3% | +5.2% |
| Q4 FY2023 | $0.48 | $0.56 | -13.5% | -3.8% | -2.9% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Maintained2025-07-15
- Q1 FY2024Maintained2024-04-15
- Q4 FY2024Lowered2024-13-15
- Q3 FY2024Suspended2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Paul JosephsCEO1 yr 6 mo5 callsCurrentSample
CEO since 2024 • 3/4 beats (75%) • last call held guidance Q3 FY2025
- Ryan David LakeCFO1 yr 9 mono recorded callsCurrentSample
CFO since 2024 • 3/4 beats (75%) • guidance suspended Q1 FY2025
- Thomas D SalusChief Legal & Administration1 yr 2 mono recorded callsCurrentSample
OTHER since 2025 • 2/2 beats (100%) • guidance suspended Q3 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LFCR.
$ curl https://api.spokenalpha.com/v1/companies/LFCRFAQ
Frequently asked about LFCR
Where can I find LIFECORE BIOMEDICAL, INC. \DE\'s (LFCR) earnings call transcripts?
Spoken Alpha indexes LFCR's earnings call transcripts at https://spokenalpha.com/companies/LFCR. Each call links to attributed speakers and parsed analyst Q&A.
When was LIFECORE BIOMEDICAL, INC. \DE\'s most recent earnings call?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) held its most recent earnings call on 2026-03-16, covering fiscal Q4 2025.
What sector is LFCR in?
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).